New treatments targeting the basic defects in cystic fibrosis

Presse Medicale

Volumn 46, Issue 6P2, 2017, Pages e165-e175

  Fajac, Isabelle ^a,b   Wainwright, Claire E ^c,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Institut Cochin   (France)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d LADY CILENTO CHILDREN S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; ATALUREN; CAVOSONSTAT; CHLORIDE CHANNEL; COMPLEMENTARY DNA; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL SODIUM CHANNEL; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; IVACAFTOR; LENTIVIRUS VECTOR; LUMACAFTOR; MESSENGER RNA; PLACEBO; PLASMID DNA; PTI 428; STABILIZING AGENT; TEZACAFTOR; TOBRAMYCIN; UNCLASSIFIED DRUG; VX 371; AMINOPHENOL DERIVATIVE; CFTR PROTEIN, HUMAN; CHLORIDE CHANNEL STIMULATING AGENT; QUINOLONE DERIVATIVE;

CFTR GENE; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG MECHANISM; GENE; GENE MUTATION; GENE THERAPY; HEALTH CARE COST; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; ADOLESCENT; ADULT; CHILD; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; EXOCRINE PANCREATIC INSUFFICIENCY; GENETICS; INFANT; INTERDISCIPLINARY COMMUNICATION; INTERSECTORAL COLLABORATION; LIFE EXPECTANCY; MORTALITY; NEWBORN; PHENOTYPE; PRESCHOOL CHILD; PROCEDURES; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AMINOPHENOLS; CHILD; CHILD, PRESCHOOL; CHLORIDE CHANNEL AGONISTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA MUTATIONAL ANALYSIS; EXOCRINE PANCREATIC INSUFFICIENCY; GENETIC THERAPY; HUMANS; INFANT; INFANT, NEWBORN; INTERDISCIPLINARY COMMUNICATION; INTERSECTORAL COLLABORATION; LIFE EXPECTANCY; PHENOTYPE; PROGNOSIS; QUINOLONES; YOUNG ADULT;

EID: 85019832983     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2017.01.024     Document Type: Short Survey

References (62)

1. Farrell, P.M., The prevalence of cystic fibrosis in the European Union. J Cyst Fibros 7 (2008), 450–453.
2. Anderson, D.H., Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathological study. Am J Dis Child 56 (1938), 344–399.
3. Quinton, P.M., Chloride impermeability in cystic fibrosis. Nature 301 (1983), 421–422.
4. Knowles, M.R., Carson, J.L., Collier, A.M., Gatzy, J.T., Boucher, R.C., Measurements of nasal transepithelial electric potential differences in normal human subjects in vivo. Am Rev Respir Dis 124 (1981), 484–490.
5. Riordan, J.R., Rommens, J.M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245 (1989), 1066–1073.
6. Sheppard, D.N., Welsh, M.J., Structure and function of the CFTR chloride channel. Physiol Rev 79 (1999), S23–S45.
7. Cohen-Cymberknoh, M., Shoseyov, D., Kerem, E., Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 183 (2011), 1463–1471.
8. Castellani, C., Cuppens, H., Macek, M. Jr., Cassiman, J.J., Kerem, E., Durie, P., et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 7 (2008), 179–196.
9. Sosnay, P.R., Siklosi, K.R., Van Goor, F., Kaniecki, K., Yu, H., Sharma, N., et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 45 (2013), 1160–1167.
10. Ferec, C., Cutting, G.R., Assessing the disease-liability of mutations in CFTR. Cold Spring Harb Perspect Med, 2, 2012, a009480.
11. Hwang, T.C., Kirk, K.L., The CFTR ion channel: gating, regulation, and anion permeation. Cold Spring Harb Perspect Med, 3, 2013, a009498.
12. Stoltz, D.A., Meyerholz, D.K., Welsh, M.J., Origins of cystic fibrosis lung disease. N Engl J Med 372 (2015), 351–362.
13. Button, B., Cai, L.H., Ehre, C., Kesimer, M., Hill, D.B., Sheehan, J.K., et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science 337 (2012), 937–941.
14. Knowles, M.R., Boucher, R.C., Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 109 (2002), 571–577.
15. Quinton, P.M., Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 372 (2008), 415–417.
16. Pezzulo, A.A., Tang, X.X., Hoegger, M.J., Alaiwa, M.H., Ramachandran, S., Moninger, T.O., et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 487 (2012), 109–113.
17. Mall, M.A., Boucher, R.C., Pathophysiology of cystic fibrosis lung disease. Eur Respir Monogr 64 (2014), 1–13.
18. Welsh, M.J., Smith, A.E., Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73 (1993), 1251–1254.
19. Zielenski, J., Tsui, L.C., Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 29 (1995), 777–807.
20. Brodlie, M., Haq, I.J., Roberts, K., Elborn, J.S., Targeted therapies to improve CFTR function in cystic fibrosis. Genome Med, 7, 2015, 101.
21. Mall, M.A., Galietta, L.J., Targeting ion channels in cystic fibrosis. J Cyst Fibros 14 (2015), 561–570.
22. Ramsey, B.W., Davies, J., McElvaney, N.G., Tullis, E., Bell, S.C., Drevinek, P., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365 (2011), 1663–1672.
23. Davies, J.C., Wainwright, C.E., Canny, G.J., Chilvers, M.A., Howenstine, M.S., Munck, A., et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 187 (2013), 1219–1225.
24. McKone, E.F., Borowitz, D., Drevinek, P., Griese, M., Konstan, M.W., Wainwright, C., et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med 2 (2014), 902–910.
25. De Boeck, K., Munck, A., Walker, S., Faro, A., Hiatt, P., Gilmartin, G., et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros 13 (2014), 674–680.
26. Moss, R.B., Flume, P.A., Elborn, J.S., Cooke, J., Rowe, S.M., McColley, S.A., et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med 3 (2015), 524–533.
27. Davies, J.C., Cunningham, S., Harris, W.T., Lapey, A., Regelmann, W.E., Sawicki, G.S., et al. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med 4 (2016), 107–115.
28. Taylor-Cousar, J., Niknian, M., Gilmartin, G., Pilewski, J.M., Investigators VX. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: safety and efficacy in an expanded access program in the United States. J Cyst Fibros 15 (2016), 116–122.
29. Sawicki, G.S., McKone, E.F., Pasta, D.J., Millar, S.J., Wagener, J.S., Johnson, C.A., et al. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med 192 (2015), 836–842.
30. Accurso, F.J., Van Goor, F., Zha, J., Stone, A.J., Dong, Q., Ordonez, C.L., et al. Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. J Cyst Fibros 13 (2014), 139–147.
31. Van Goor, F., Hadida, S., Grootenhuis, P.D., Burton, B., Stack, J.H., Straley, K.S., et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 108 (2011), 18843–18848.
32. Van Goor, F., Hadida, S., Grootenhuis, P.D., Burton, B., Cao, D., Neuberger, T., et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 106 (2009), 18825–18830.
33. Clancy, J.P., Rowe, S.M., Accurso, F.J., Aitken, M.L., Amin, R.S., Ashlock, M.A., et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67 (2012), 12–18.
34. Flume, P.A., Liou, T.G., Borowitz, D.S., Li, H., Yen, K., Ordonez, C.L., et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 142 (2012), 718–724.
35. Wainwright, C.E., Elborn, J.S., Ramsey, B.W., Marigowda, G., Huang, X., Cipolli, M., et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373 (2015), 220–231.
36. Milla, C., Ratjen, F., Marigowda, G., Liu, F., Waltz, D., Rosenfeld, M., Safety, tolerability, and pharmacodynamics of combination lumacaftor/ivacaftor therapy in patients aged 6-11 years with CF homozygous for the F508del-CFTR mutation. Pediatr Pulmonol, 51, 2016, S259.
37. Veit, G., Avramescu, R.G., Perdomo, D., Phuan, P.W., Bagdany, M., Apaja, P.M., et al. Some gating potentiators, including VX-770, diminish DeltaF508-CFTR functional expression. Sci Transl Med, 6, 2014, 246ra97.
38. Cholon, D.M., Quinney, N.L., Fulcher, M.L., Esther, C.R. Jr., Das, J., Dokholyan, N.V., et al. Potentiator ivacaftor abrogates pharmacological correction of DeltaF508 CFTR in cystic fibrosis. Sci Transl Med, 6, 2014, 246ra96.
39. Dekkers, J.F., Gogorza Gondra, R.A., Kruisselbrink, E., Vonk, A.M., Janssens, H.M., de Winter-de Groot, K.M., et al. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids. Eur Respir J 48 (2016), 451–458.
40. Howard, M., Frizzell, R.A., Bedwell, D.M., Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 2 (1996), 467–469.
41. Wilschanski, M., Famini, C., Blau, H., Rivlin, J., Augarten, A., Avital, A., et al. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 161 (2000), 860–865.
42. Sermet-Gaudelus, I., Boeck, K.D., Casimir, G.J., Vermeulen, F., Leal, T., Mogenet, A., et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 182 (2010), 1262–1272.
43. Kerem, E., Hirawat, S., Armoni, S., Yaakov, Y., Shoseyov, D., Cohen, M., et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 372 (2008), 719–727.
44. Kerem, E., Konstan, M.W., De Boeck, K., Accurso, F.J., Sermet-Gaudelus, I., Wilschanski, M., et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2 (2014), 539–547.
45. Zaman, K., Sawczak, V., Zaidi, A., Butler, M., Bennett, D., Getsy, P., et al. Augmentation of CFTR maturation by S-nitrosoglutathione reductase. Am J Physiol Lung Cell Mol Physiol 310 (2016), L263–L270.
46. Griesenbach, U., Pytel, K.M., Alton, E.W., Cystic fibrosis gene therapy in the UK and elsewhere. Hum Gene Ther 26 (2015), 266–275.
47. Alton, E.W., Armstrong, D.K., Ashby, D., Bayfield, K.J., Bilton, D., Bloomfield, E.V., et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 3 (2015), 684–691.
48. Alton, E.W., Beekman, J.M., Boyd, A.C., Brand, J., Carlon, M.S., Connolly, M.M., et al. Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. Thorax 72 (2017), 137–147.
49. Schwank, G., Koo, B.K., Sasselli, V., Dekkers, J.F., Heo, I., Demircan, T., et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13 (2013), 653–658.
50. Zamecnik, P.C., Raychowdhury, M.K., Tabatadze, D.R., Cantiello, H.F., Reversal of cystic fibrosis phenotype in a cultured Delta508 cystic fibrosis transmembrane conductance regulator cell line by oligonucleotide insertion. Proc Natl Acad Sci U S A 101 (2004), 8150–8155.
51. Gentzsch, M., Dang, H., Dang, Y., Garcia-Caballero, A., Suchindran, H., Boucher, R.C., et al. The cystic fibrosis transmembrane conductance regulator impedes proteolytic stimulation of the epithelial Na+ channel. J Biol Chem 285 (2010), 32227–32232.
52. Knowles, M.R., Church, N.L., Waltner, W.E., Yankaskas, J.R., Gilligan, P., King, M., et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 322 (1990), 1189–1194.
53. Graham, A., Hasani, A., Alton, E.W., Martin, G.P., Marriott, C., Hodson, M.E., et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 6 (1993), 1243–1248.
54. Althaus, M., ENaC inhibitors and airway re-hydration in cystic fibrosis: state of the art. Curr Mol Pharmacol 6 (2013), 3–12.
55. Moss, R.B., Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. J Pediatr 162 (2013), 676–680.
56. Schork, N.J., Personalized medicine: Time for one-person trials. Nature 520 (2015), 609–611.
57. Rowe, S.M., Heltshe, S.L., Gonska, T., Donaldson, S.H., Borowitz, D., Gelfond, D., et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 190 (2014), 175–184.
58. Siracusa, C.M., Ryan, J., Burns, L., Wang, Y., Zhang, N., Clancy, J.P., et al. Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor. J Cyst Fibros 14 (2015), 621–626.
59. Bellin, M.D., Laguna, T., Leschyshyn, J., Regelmann, W., Dunitz, J., Billings, J., et al. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diabetes 14 (2013), 417–421.
60. Reinhardt, U., Probing our moral values in health care: the pricing of specialty drugs. JAMA 314 (2015), 981–982.
61. Ferkol, T., Quinton, P., Precision medicine: at what price?. Am J Respir Crit Care Med 192 (2015), 658–659.
62. Merlin, T., Farah, C., Schubert, C., Mitchell, A., Hiller, J.E., Ryan, P., Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies. Med Decis Making 33 (2013), 333–342.